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INTRODUCTION 
Activation of lung phagocytes, whether involving residential or recruited phagocytic 
cells (macrophages, monocytes, neutrophils), results in a series of products important 
for development of inflammatory injury of the lung. An understanding of the mecha- 
nisms of cell activation as well as how products of these activated cells interact with 
cellular and non-cellular targets to bring about tissue damage is important for the ul- 
timate use of blocking interventions in the treatment of human inflammatory dis- 
eases. In these considerations, we will discuss cytokine products of activated 
macrophages, including pro-inflammatory cytokines, anti-inflammatory cytokines, 
oxidants, and proteinases (TABLE 1). All of the information to be presented in this pa- 
per derives from the study of an animal model of acute lung injury induced by intra- 
pulmonary deposition of IgG immune complexes. This deposition results in a com- 
plement-dependent activation of lung macrophages, recruitment of large numbers of 
neutrophils, and ultimate damage of lung cells and matrix as a result of numerous 
products from activated macrophages and recruited (and activated) neutrophils. 
Damage in this lung model can be precisely quantitated by extravascular leakage of 
I2’I-labeled albumin from the blood, extravasation of 51Cr-labeled rat RBC, and 
build-up of neutrophils (as measured by lung content of myeloperoxidase (MPO) or 
retrieval of neutrophils from bronchoalveolar lavage (BAL) fluids). Cytokine content 
is usually measured in BAL fluids, although whole lung homogenates can also be 
employed. The IgG immune complex model may provide information relevant to an 
understanding of human inflammatory diseases triggered by deposition of IgG im- 
mune complexes, such as rheumatoid arthritis, systemic lupus erythematosus, vas- 
culitis, membranous glomerulonephritis, idiopathic pulmonary fibrosis, etc. 
PRO-INFLAMMATORY CYTOKINES/CHEMOKINES 
There are at least three different functional categories of cytokineskhemokines as 
defined by their pro-inflammatory effects: Cytokines include the traditional products 
such as TNFa, IL-1, interferon-gamma (IFNy), etc., while chemokines include the 
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TABLE 1. Inflammatory Products of Lung Macrophages in Lung Injury 
A. Pro-inflammatory cytokines/chemokines 
i. Induction of endothelial adhesion molecules (TNFa, IL-I) 
ii. Chemotactic activity, especially the a chemokines of the IL-8 family (MIP-2, CMC, 
etc.) 
iii. Other activities of chemokines (e.g., the p chemokine, MIP-la) 
B. Anti-inflammatory cytokines (IL-4, IL-10) 
C. Oxidants 
i. Products of inducible nitric oxide synthase (iNOS) 
a. Lung sources of iNOS 
b. Inducers of iNOS 
c. Evidence for in vivo role of .NO 
D. Proteinases 




ii. Serine proteinases 
a. Elastase 
b. Cathepsins 
IL-8 family of a chemokines (chemically characterized by C-X-C linkages and in- 
cluding products such as IL-8; MIP-2; PF-4; GROa,P,y; KC, etc.) and the P 
chemokines (chemically characterized by C-C linkages and including products such 
as MCP-1,2,3; MIP-la,P; RANTES; Eotaxin; etc.). In the IgG immune complex 
model of acute lung injury, bronchoalveolar (BAL) fluids as a function of time con- 
tain large amounts of biologically active TNFa and IL-1. Although these cytokines 
are known to have the ability to activate macrophages and neutrophils, alone each cy- 
tokine has fairly limited in vitro activity, best described as “priming” of these cells 
for enhanced responses to other stimuli (e.g., cytokines, immune complexes, 
lipopolysaccharide, etc.). A major function of TNFa and IL-I in lung appears to be 
induction of endothelial adhesion molecules, ICAM- 1 and E-selectin, both of which 
are critical for the early steps required in neutrophil adhesion to the activated en- 
dothelium and eventual transmigration of neutrophils into the alveolar compartment 
in the inflammatory model described above.2 Blocking of TNFa by antibody or by 
soluble TNFa receptor-I, or blocking of IL- 1 by antibody or by IL- 1 receptor antago- 
nist resulted in dramatically diminished recruitment of neutrophils and reduced de- 
velopment of lung injury. In the case of blockade of TNFa, these results could be at- 
tributed to greatly reduced upregulation of lung vascular ICAM-I as determined by 
the use of quantitative fixation of ‘Z51-anti-ICAM- 1 to the lung vasculature. Although 
studies with blockade of IL- 1 are incomplete, the trends also suggest that IL- 1 func- 
tions in this model in a similar manner to that of TNFa. These data strongly suggest 
that the “early response cytokines,” TNFa and IL- 1, function in a pro-inflammatory 
manner by playing a key role in upregulation of lung vascular ICAM-1 and E-se- 
lectin, which are critically necessary for neutrophil recruitment. 
Another functional classification of cytokineslchemokines derives from their 
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chemotactic a c t i ~ i t y . ~ . ~  Some of the a chemokines (IL-8 or its family relatives, such 
as MIP-2 and CINC, KC and others) and some of the p chemokines (MIP-la$; 
MCP-1,2 and 3; RANTES; and others) are well known for the chemotactic activities, 
the a chemokine family being described as having activity chiefly for neutrophils 
(and to a lesser extent for T cell subsets), while the p chemokines are thought to be 
predominantly chemotactic for monocytes and lymphocytes. It is clear that this func- 
tional classification cannot be strictly relied upon for predictions of the in vivo role of 
these chemokines. In the IgG immune complex model of injury in rats, message for 
MIP-2 appears within 2 h and is maintained for the next 4 h, followed by decline. 
MIP-2 protein followed a similar, albeit slightly delayed, pattern of expression. Most 
importantly, blocking of rat MIP-2 by antibody was significantly protective, resulting 
in reduced influx of neutrophils and diminishing degree of lung damage, without af- 
fecting BAL levels of TNFw5 These data indicate that MIP-2 is important in this in- 
flammatory model and may be functioning chiefly as a chemotactic attractant for 
neutrophils. A second a chemokine that seems to play an important role in this in- 
flammatory model is the chemokine-induced neutrophil chemotactic factor (CINC), 
which is expressed in a manner similar to that described for MIP-2 (as above). Block- 
ing of CINC similarly suppresses neutrophil recruitment and development of lung in- 
jury.6 Thus, at least two a chemokines play important roles in these reactions and 
seem to function as neutrophil chemoattractants. A third proinflammatory function 
of the chemokines derives from our studies in the rat lung model of IgG immune 
complex injury, in which MIP-la expression has been demonstrated (both by mRNA 
and by protein) in the first 2-6 h of the developing reaction. Antibody-induced block- 
ing of MIP-la results in suppressed recruitment of neutrophils and reduced leakage 
of '251-albumin. In striking contrast to the protective effects of blockade of MIP-2 
and CINC, blockade of MIP-la is also associated with substantial reductions in lev- 
els of TNFa in BAL fluids.' This has led to the conclusion that in this model the p 
chemokine MIP-la functions as an autocrine regulator of TNFa production, the end 
result being enhanced upregulation of lung vascular ICAM-1 by tissue macrophages. 
Accordingly, as compared to MIP-2 and CINC, this chemokine appears to play a very 
different functional role in the inflammatory response. 
ANTI-INFLAMMATORY CYTOKINES 
Another functional classification of cytokines comes from the recognition that 
certain cytokines have very clearly been shown to have anti-inflammatory functions, 
especially IL-4 and IL-10. A major function of these cytokines has been suggested by 
their in vitro ability to suppress cytokine production by stimulated macro phage^.^.^ 
Our employment of these cytokines in the IgG immune complex lung injury model 
has verified that both IL-4 and IL-10 have very powerful anti-inflammatory effects.'O 
When added to the airway with anti-bovine serum albumin in minute (nanogram) 
quantities, these cytokines are profoundly suppressive, causing dramatic reductions 
in albumin leak, in intraalveolar hemorrhage, and in neutrophil accumulation. Fur- 
thermore, there are profound reductions in BAL levels of TNFa, which, in turn, has 
been shown to result in greatly reduced lung vascular ICAM-1 expression. In the 
case of IL-10, in vivo blocking of this cytokine increases the level of TNFa in BAL 
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fluids, accompanied by increased accumulation of neutrophils and intensified injury, 
whereas antibody to IL-4 has no effect1' These data suggest that, in this model of 
lung injury, intrinsic IL-10 regulates the intensity of inflammatory damage by con- 
trolling the level of TNFa produced, and, correspondingly, the upregulation of 
ICAM- 1, an essential adhesion molecule in this inflammatory model. It seems likely 
that there may be additional intrinsic cytokines with anti-inflammatory activity, such 
as IL-6 and IL- 13. 
OXIDANT PRODUCTS OF PHAGOCYTIC CELLS 
Using the IgG immune complex model of inflammatory lung injury, evidence 
suggests that two oxidant-generating pathways in lung macrophages and neutrophils 
contribute to development of lung injury. These pathways are described in FIGURE 1. 
The first oxidant-generating pathway features inducible nitric oxide synthase 
(iNOS). This enzyme is inducible in lung macrophages by the action of three cy- 
tokines: TNFa, IL-1, and interferon gamma (INFy). In the in vivo model described 
above, blockade of any one of these three cytokines produces partial protection from 
TNFa, IL-1, IFN-y 
iNOS 
L-arg 
=NO + citrulline 











FIGURE 1. Sources of oxidants generated by activated phagocytic cells, featuring inducible 
nitric oxide synthase (iNOS) and NADPH oxidase. The intersection between the two pathways 
occurs between superoxide anion (O,.) and nitric oxide (.NO). 
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lung injury and partial reduction in nitric oxide (.NO) generation (as quantitated by 
formation of NO2- (NO3-), whereas in  vivo blockade of all three cytokines (by anti- 
bodies) almost totally suppresses .NO production and greatly attenuates development 
of lung injury.I2 In the .NO generating pathway, iNOS converts L-arginine into .NO 
and citrulline. .NO can then react with available superoxide anion (O,.) to produce 
the highly reactive peroxynitrite anion (.ONOO) which, when protonated (to form 
HONOO) in an acidic environment can undergo hemolytic cleavage to generate the 
hydroxyl radical (HO.), which is also highly reactive, The ultimate breakdown prod- 
ucts of this pathway are nitrite (NO,-) and nitrate (NO3-), which are the usual chemi- 
cal surrogates for detection of .NO. Evidence for the role of the .NO pathway in this 
inflammatory model was obtained by the airway instillation of analogues of L-argi- 
nine, namely, L - N ~  monomethyl arginine and related  compound^.'^ Acting as com- 
petitive inhibitors of L-arginine, these analogues in a dose-dependent manner effec- 
tively inhibit .NO production in lung and substantially reduce development of injury. 
These protective effects are not associated with any reduction in neutrophil accumu- 
lation in these inflammatory reactions, suggesting that the 'NO-generating pathway 
is a terminal effector mechanism for tissue injury. To date, there are two identified 
lung sources of iNOS in this model of lung injury: lung macrophages and type I1 
alveolar epithelial cells.I2 This conclusion is based not only on immunostaining for 
iNOS, demonstrating its presence in these two cell types, but is also based on the 
finding that isolation from normal lung of either alveolar macrophages or type I1 
alveolar epithelial cells and their subsequent in vitro stimulation with IFNy or 
lipopolysaccharide (LPS) results in .NO production that is suppressible in the pres- 
ence of analogues of L-arginine. 
A second oxidase-generating system, NADPH oxidase, is present in both lung 
macrophages and ne~trophils. '~. '~ Upon cell activation (with phorbol ester, immune 
complexes, etc.) cytoplasmic cofactors are transposed to the cell membrane to pro- 
duce a protein complex that defines NADPH oxidase. This enzyme transfers single 
electrons, resulting in progressive reduction of O2 to 02* to H202, to HO., and finally, 
to H20. NADPH oxidase may be the key source for 02. that intercalates with the 
iNOS pathway to react with .NO, as described above. 0,. may play another important 
role in reducing Fe3+ in ferritin stores within cells to generate Fez+, a reactive transi- 
tional form that can interact with H202 to facilitate electron transport, reducing H202 
to HO., thus regenerating Fe3+.H20z can also be metabolized in the presence of chlo- 
ride and MPO to generate hypochlorous acid (HOCl), which can convert procollage- 
nase and progelatinase into their active enzyme forms (see below). The presumed 
role of NADPH oxidase in this lung injury model is not only to provide O,., perhaps 
for the iNOS pathway (see above), but also to generate HO. from H20,, as suggested 
by the protective effects of catalase and the iron chelator, deferoxamine.I6 
PHAGOCYTIC CELL PROTEINASES INVOLVED IN LUNG INJURY 
Two categories of proteinases appear to be involved in lung injury in the IgG im- 
mune complex model: metalloproteinases and serine proteinases. The most direct ex- 
perimental evidence incriminating these proteinases comes from the use of in- 
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hibitors. Metalloproteinases include collagenases and gelatinases, the latter having 
been identified in BAL fluids of animals developing IgG-immune complex-induced 
alveolitis. These enzymes derive chiefly from macrophages and, as the names imply, 
hydrolyze native or denatured collagens. Serine proteinases include elastase and 
cathepsins, derived both from macrophages and neutrophils. Elastolytic activity has 
been found in BAL fluids from inflamed rat lungs in the case of the IgG immune 
complex model (TABLE 2). The most compelling evidence for the role of these en- 
zymes has been the demonstration that airway instillation of recombinant human tis- 
sue metalloproteinase inhibitor-2 (TIMP-2) or recombinant human secreted leuko- 
cyte proteinase inhibitor (SLPI) sharply reduces the intensity of injury.” Interesting- 
ly, these protective effects are associated with reduced neutrophil accumulation, sug- 
gesting that breakdown of lung connective matrix may reduce chemotactic peptides 
that facilitate neutrophil recruitment under the experimental conditions of inflamma- 
tion. The extent to which either macrophage-derived matrix-destroying enzymes, 
such as cysteine proteinases (cathepsins B, H and L), may also be involved in these 
lung-damaging reactions remains unknown. 
CONCLUSIONS 
Products of activated phagocytic cells (lung macrophages and recruited neu- 
trophils) represent a series of toxic factors that directly or indirectly injure both lung 
cells and matrix. Furthermore, there is evidence for synergy between the effects of 
oxidants and proteinases. The interplay of cytokineskhemokines in lung inflammato- 
ry reactions triggered by intrapulmonary deposition of IgG immune complexes is 
complicated. On the one hand, these inflammatory reactions cause production of a 
series of pro-inflammatory products that facilitate upregulation of endothelial adhe- 
sion molecules, chemotactic recruitment of neutrophils, and positive autocrine stimu- 
lation of macrophages productive of more cytokine generation. Yet these inflammato- 
ry reactions are also associated with macrophage products (cytokines) that downreg- 
ulate the inflammatory response. Understanding the complex biological responses 
could set the stage for more specific approaches for blocking of the inflammatory re- 
sponse in a variety of human inflammatory diseases. 
TABLE 2. Evidence for Role of Proteinases in IgG Immune Complex Alveolitis 
Intervention 
Reduction (%) in Lung 
Leak of Albumin 
rhu TIMP-2 (0.5 rng) 
rhu TIMP-2 ( 1  .O rng) 
rhu SLPI (1 .O rng) 
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